RxSight, Inc. (NASDAQ:RXST) Holdings Boosted by Quantbot Technologies LP

Quantbot Technologies LP grew its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 31.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,444 shares of the company’s stock after purchasing an additional 8,041 shares during the quarter. Quantbot Technologies LP owned approximately 0.08% of RxSight worth $1,150,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in RXST. Quarry LP boosted its position in RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of RxSight during the third quarter worth about $34,000. Private Trust Co. NA acquired a new stake in shares of RxSight in the 4th quarter worth about $34,000. Arcadia Investment Management Corp MI bought a new stake in RxSight in the 4th quarter valued at about $46,000. Finally, Harbor Investment Advisory LLC bought a new stake in RxSight in the 4th quarter valued at about $52,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

RxSight Stock Down 0.9 %

NASDAQ:RXST opened at $24.70 on Wednesday. RxSight, Inc. has a 52-week low of $24.09 and a 52-week high of $66.54. The firm has a market cap of $1.00 billion, a P/E ratio of -29.76 and a beta of 1.22. The business’s 50-day moving average price is $29.40 and its 200 day moving average price is $39.55.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $40.21 million for the quarter, compared to analyst estimates of $40.23 million. Sell-side analysts expect that RxSight, Inc. will post -0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on RXST. Stifel Nicolaus dropped their price target on shares of RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 target price on shares of RxSight in a research note on Wednesday, February 26th. Bank of America decreased their price target on RxSight from $60.00 to $36.00 and set a “buy” rating for the company in a research note on Friday, March 21st. JPMorgan Chase & Co. lowered their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Finally, Wells Fargo & Company decreased their target price on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, RxSight presently has an average rating of “Moderate Buy” and an average price target of $49.33.

Insiders Place Their Bets

In other RxSight news, Director Jesse Anderson Corley purchased 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $31.18 per share, with a total value of $44,992.74. Following the completion of the transaction, the director now owns 1,443 shares of the company’s stock, valued at approximately $44,992.74. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now owns 24,793 shares of the company’s stock, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.